I disagree about entities 'throwing' money at researchers. I heard from one researcher who said they spend about 80% of their time writing grant proposals, and maybe one in 20 of those might get funded. This person is chair of a department at an NCI center. To me, this is a huge waste of their time and knowledge.
Cancer is complex. Some breast tumors differ from cell to cell, and drug resistance can develop relatively quickly (after a few treatment cycles). That said, having spoken with a pediatric oncologist, they said that most of the gains in the past 20 years were due to scheduling and dosing, so new drugs are not always what show improved outcomes.
For me, one of my three lymphomas, Hodgkin's lymphoma, has a high cure rate using drugs that have been around for decades. However, if Hodgkin's returns it is difficult to treat with drugs, in which case stem cell transplants can be life saving, and in my case, curative for Follicular lymphoma that has no known drug cure. Transplants though are high risk, often due to infections .... beating the cancer but succumbing to an infection is not uncommon. So drugs and complimentary treatments are both important.
My personal interests, which many of you runners might identify with, is how does the timing of exercise affect cancer treatments? We all probably have a pre-race routine: meal the night before, plus coffee, water, bathroom, and stretching the morning of a competition. There really isn't this for cancer treatments, but could it help, or harm? An excellent review was recently published if you can get access: Exercise Is Medicine, But Does It Interfere
With Medicine?
http://journals.lww.com/acsm-essr/Abstract/2017/07000/Exercise_Is_Medicine,_But_Does_It_Interfere_With.3.aspx
From the article: Future Perspectives
"This review highlights the physiological changes to acute and chronic exercise that have, in our opinion, a well-founded potential for a direct effect on drug pharmacokinetics (PK). This review provides an update of the most influential Exercise-PK interactions and introduces the topics of subacute and chronic exercise adaptations that also could affect PK. The magnitude of the exercise-induced changes in many of these variables is extreme compared with the changes observed in disease or injury states that many drugs are prescribed to treat, which makes it all the more surprising that Exercise-PK interactions have received such limited attention.
As we encourage exercise in more at-risk and special populations that also are ingesting drugs regularly (e.g., cancer patients, psychiatric patients), the rationale for appropriately titrated drug doses becomes all the more important, particularly for drugs with narrow therapeutic windows. Moreover, the extreme physiological perturbations to acute exercise typically experienced on a regular basis by athletes pose lots of questions about drug efficacy and safety for this population as well. This brief review should motivate others to explore Exercise-PK interactions with a view to clarifying and improving drug efficacy and safety."
Immunotherapies look to be promising since cancers develop ways to avoid detection by our immune systems. Reprogramming our own immune system to overcome this, or using immune cells from donors in new ways are also being developed. Steve Keith, the women's XC & Track coach at Vanderbilt just had a second stem cell transplant using something relatively new called a haplo transplant, which used half strands of his brother's DNA (if I understand this correctly). Additionally, lactate at the lactate threshold also affects Natural Killer cells, part or our innate immune system that responds quickly to cancerous cells. Exercise plays a preventative role in cancer, but perhaps too intense exercise for too many years might have the opposite affect on immune cells, we just don't know yet. Stress can be good as we adapt to it, but chronic stress can exhaust subsets of the immune system.
Lastly, I do think some charity runners grossly misunderstand their funding efforts. There is some fudge room on these figures, but here's an example. A large marathon charges charities $400 just for the charity bib (registration is separate), and a charity may require a minimum of $3,000 be raised by the runner for the bib. One payment processor associated with events charges 12%, deduct a charity funded race kit, bus to the start, maybe a group dinner, start line coffee, etc. and perhaps another $100 +/- is spent. According to The American Cancer Society's (ACS) 2014 IRS Form 990 (Part II line 4a / Part I line 12) they spent ~ 17% on research.
https://www.cancer.org/content/dam/cancer-org/online-documents/en/pdf/policies/acspc-045866.pdf
The percentage goes up if prevention and support programs are included (62%). Doing the math: $3,000 - $360 (processor) - $400 (charity bib charge) - $100 (miscellaneous) = $2,140 x 17% = $363.80 toward RESEARCH, using ACS in this example. That's only 12% of the $3,000 minimum actually going to research. However, the more one raises the better the net is, but this isn't including the costs, if any, of getting to and from and staying in a marathon city. I'd rather see more research labs with direct deposits, but then again, most people wouldn't know who to send their money to, so cancer foundations can serve a purpose.
By the way, Brian Druker, M.D., who was instrumental in development of the best cancer drug to date, Gleevec, is a runner. He's also Director of the Knight Cancer Institute at Oregon Health Sciences University, and yes, it's that Knight, Nike co-founder Phil Knight. It was interesting reading not too long ago some of the anti-Nike posts on LetsRun while at the same time seeing ads on the homepage of LetsRun for the Leukemia & Lymphoma Society that had Dr. Druker's picture in them.
We're all in this together!
Ken Martin
Survivor: Hodgkin's, Follicular, and Diffuse Large B-Cell lymphomas
2013 Allogeneic stem cell transplant recipient
3:57.81 mile
2:09:38 marathon
exercise-oncology advocate